Retatrutide 20 mg: is a chain of amino acids injected weekly subcutaneously for weight loss, metabolism and reproductive system health. It acts on the mitochondria to better control insulin and remove both visceral fat and subcutaneous fat. Unlike the Semiglutide and tripartite predecessors it contains it also acts as a myostatin inhibitor to prevent muscle loss.
How It Works
• GLP-1 (Glucagon-like peptide-1): Lowers appetite, slows digestion (gastric emptying), and increases feelings of fullness.
• GIP (Glucose-dependent insulinotropic polypeptide): Improves how the body handles nutrients and insulin release while easing digestive side effects.
• Glucagon (GCG): Increases calorie burn (energy expenditure) and stimulates the breakdown of stored body fat and liver fat.
Warnings:
Consult with doctor regarding any current health problems that can be impacted by weekly use.
Current Status and Uses
Approval Status: Not yet FDA-approved; it is currently undergoing Phase 3 clinical trials.
Conditions Studied: Being evaluated for chronic weight management (obesity and overweight), type 2 diabetes, fatty liver disease (MASLD/MASH), and knee osteoarthritis.
Efficacy: Early clinical trials showed average body weight reductions of up to 24% to nearly 30% at higher doses over extended periods. [1, 2, 3, 4, 5]
Potential Side Effects and Risks
Common Effects: Mild-to-moderate gastrointestinal issues like nausea, diarrhea, vomiting, and constipation.
Retatrutide 20 mg: is a chain of amino acids injected weekly subcutaneously for weight loss, metabolism and reproductive system health. It acts on the mitochondria to better control insulin and remove both visceral fat and subcutaneous fat. Unlike the Semiglutide and tripartite predecessors it contains it also acts as a myostatin inhibitor to prevent muscle loss.
How It Works
• GLP-1 (Glucagon-like peptide-1): Lowers appetite, slows digestion (gastric emptying), and increases feelings of fullness.
• GIP (Glucose-dependent insulinotropic polypeptide): Improves how the body handles nutrients and insulin release while easing digestive side effects.
• Glucagon (GCG): Increases calorie burn (energy expenditure) and stimulates the breakdown of stored body fat and liver fat.
Warnings:
Consult with doctor regarding any current health problems that can be impacted by weekly use.
Current Status and Uses
Approval Status: Not yet FDA-approved; it is currently undergoing Phase 3 clinical trials.
Conditions Studied: Being evaluated for chronic weight management (obesity and overweight), type 2 diabetes, fatty liver disease (MASLD/MASH), and knee osteoarthritis.
Efficacy: Early clinical trials showed average body weight reductions of up to 24% to nearly 30% at higher doses over extended periods. [1, 2, 3, 4, 5]
Potential Side Effects and Risks
Common Effects: Mild-to-moderate gastrointestinal issues like nausea, diarrhea, vomiting, and constipation.